The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled patient's risk of cancer relapse and death, and five or more CTCs increased recurrence by 400 percent ...
Dec 10, 2010
5 / 5 (1)
0
For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San ...
Dec 10, 2010
not rated yet
0
Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd ...
Dec 10, 2010
not rated yet
0
The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.
Dec 10, 2010
not rated yet
0
Exemestane, an aromatase inhibitor that blocks production of estrogen, may provide another post-surgery option for postmenopausal women with hormone-receptor positive, early-stage breast cancer.
Dec 09, 2010
not rated yet
0
Obesity was associated with worse overall and disease-free survival in women with operable breast cancer treated with adjuvant chemotherapy, but for the first time, researchers observed this finding in only a specific subset ...
Dec 09, 2010
4 / 5 (1)
0
While endogenous estrogen (i.e., estrogen produced by ovaries and by other tissues) does have a well-known carcinogenic impact, hormone replacement therapy (HRT) utilizing estrogen alone (the exogenous estrogen) provides ...
Dec 09, 2010
not rated yet
0
Only half of eligible women in the United States are getting their annual mammograms, even if they have insurance to pay for the procedure, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer ...
Dec 09, 2010
not rated yet
0
Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.
Dec 09, 2010
not rated yet
0
Widespread genetic testing for Lynch Syndrome appears to be a cost-effective strategy for identifying those at risk for colorectal and endometrial cancer, according to a report in Cancer Prevention Research, a journal of the ...
Nov 19, 2010
not rated yet
0
Ninety percent of children who lived in a house where an adult smoked had evidence of tobacco-related carcinogens in their urine, according to research presented at the Ninth AACR Frontiers in Cancer Prevention Research Conference, ...
Nov 09, 2010
not rated yet
1
Men with history of fracture and comorbidities are at an increased risk of fracture after long-term use of androgen deprivation therapy, and initiating this therapy should be carefully considered in older men with localized ...
Nov 09, 2010
5 / 5 (1)
0
Researchers have further established that long-term use of statins is unlikely to substantially increase or decrease overall cancer risk, according to study results presented at the Ninth Annual AACR Frontiers in Cancer Prevention ...
Nov 09, 2010
2 / 5 (1)
2
Women planning on taking hormone therapy for the treatment of menopausal symptoms should be aware of a possible increased risk for ovarian cancer, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention ...
Nov 09, 2010
5 / 5 (1)
0
Women being treated for breast cancer with aromatase inhibitors may experience extremely low estrogen levels resulting in a wide variety of side effects that a typical postmenopausal woman without cancer may not experience.
Nov 09, 2010
5 / 5 (1)
0
